New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
|Videos|February 18, 2021
New Deterrent Stimulants for ADHD
Author(s)Timothy Wilens, MD
What observations are being noted in the field with new agents for the treatment of ADHD?
Advertisement
Timothy Wilens, MD, talks about the presentation of the APSARD 2021 conference on ADAIR Pharmacokinetics and Pharmacodynamic Data. More on the presentation can be found
Dr Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital.
Advertisement
Related to this article
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Review news in psychiatry from the last week.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
4
Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
5